NEOS - Neos Therapeutics, Inc.
| Previous Close | 1.9600 |
| Open | 1.9700 |
| Bid | 1.30 x 1400 |
| Ask | 2.30 x 900 |
| Day's Range | 1.7417 - 2.0100 |
| 52 Week Range | 1.6510 - 11.6900 |
| Volume | 627,268 |
| Avg. Volume | 512,384 |
| Market Cap | 91.901M |
| Beta (3Y Monthly) | 2.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | Mar 13, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.83 |
- GlobeNewswire•19 days ago
Neos Therapeutics Announces Realignment of Commercial Organization
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing, and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it completed a strategic assessment of its commercial business and is realigning its commercial organization for its attention deficit hyperactivity disorder (ADHD) products Adzenys XR-ODT®, Cotempla XR-ODT® and Adzenys-ER™ in order to accelerate its path to profitability.
- GlobeNewswire•22 days ago
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer, effective November 30. “Vipin was chosen in a very competitive selection process and we are very excited to have him join Altimmune as President and CEO,” said Mitch Sayare, Chairman of the Board of Altimmune. “His extensive experience and success in building, managing, and financing private and public biotech companies makes him an extraordinary fit for Altimmune.
- GlobeNewswire•22 days ago
Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•last month
Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Neos Therapeutics Inc Earnings Call
- Zacks•last month
Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Neos Therapeutics: 3Q Earnings Snapshot
The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...
- GlobeNewswire•last month
Neos Therapeutics Reports Third Quarter 2018 Financial Results
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical.
- GlobeNewswire•last month
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and.
- GlobeNewswire•last month
Neos Therapeutics Announces Proposed Offering of Common Stock
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it has commenced an underwritten public offering of its common stock. In addition, Neos expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- GlobeNewswire•2 months ago
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the.
Market Realist•2 months agoHow Is Johnson & Johnson’s Neuroscience Business Positioned?
Johnson & Johnson’s (JNJ) neuroscience business’s revenue remained flat in the third quarter compared to the third quarter of 2017. The business’s net revenue totaled $4.58 billion in the first nine months of 2018 compared to $4.46 billion in the same period of the previous year, reflecting a ~2.6% YoY rise. In the third quarter, in the US and international markets, Johnson & Johnson’s neuroscience business generated revenues of $651.0 million and $839.0 million, respectively, compared to $647.0 million and $851.0 million, respectively, in the third quarter of 2017.
- GlobeNewswire•2 months ago
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine).
- GlobeNewswire•2 months ago
Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options Development Strategy Leverages Neos’.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Neos Therapeutics to Present at the Cantor Global Healthcare Conference
DALLAS and FORT WORTH, Texas, Sept. 26, 2018-- Neos Therapeutics, Inc., a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of NEOS earnings conference call or presentation 8-Aug-18 12:30pm GMT
Q2 2018 Neos Therapeutics Inc Earnings Call
- Zacks•4 months ago
Neos Therapeutics (NEOS) Reports Q2 Loss, Lags Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -20.93% and -4.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Neos Therapeutics: 2Q Earnings Snapshot
On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 52 cents. The pharmaceutical company posted revenue of $11.4 million in the period. Neos Therapeutics shares have declined ...
- ACCESSWIRE•4 months ago
Neos Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Neos Therapeutics, Inc. (NASDAQ: NEOS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...
- TheStreet.com•6 months ago
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
The huge American Society of Clinical Oncology or ASCO confab has called it a wrap for another year. Keytruda to treat PD-1-naive advanced melanoma patients. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017.
